Tue, Dec 24, 2024
Whatsapp

Covid-19: Bharat Biotech's nasal vaccine phase III trials completed

Reported by:  PTC News Desk  Edited by:  Shgun S -- June 19th 2022 09:00 AM -- Updated: June 19th 2022 09:01 AM
Covid-19: Bharat Biotech's nasal vaccine phase III trials completed

Covid-19: Bharat Biotech's nasal vaccine phase III trials completed

Paris (France), June 19: The clinical phase III trials of Bharat Biotech's Covid-19 nasal vaccine have been completed and the company will submit its data to the Drugs Controller General of India (DCGI) next month, informed Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday. "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world's first clinically proven nasal Covid-19 vaccine," Dr Ella said. The Chairman and Managing Director of Bharat Biotech, Krishna Ella, was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year. Bharat Biotech was granted authorization to conduct standalone phase III trials on its Covid-19 nasal vaccine by India's drug controller in January of this year. DCGI nod to Bharat Biotech to conduct clinical trials of intranasal Covid-19  vaccine BBV154 Krishna stated that people who had taken the second dose of Covid-19 must also take the booster dose. "Booster dose of vaccine gives immunity. I always say the booster dose is a miracle dose for every vaccination. Even in children first, two doses don't give much immunity, but the third dose gives an amazing response to the child. The same thing for adults also. The third dose is very important for adults. Covid-19 can't be eradicated 100 per cent. It will be there and we have to live with it and handle it and more intelligently how to control it," he added. Also Read | Neeraj Chopra wins season’s first gold in Finland; escapes injury after nasty fall Nasal vaccine likely to fight new Covid-19 variants, claims study Talking about the Vivatech 2022, Krishna added that building a brand name in France is a huge achievement for India. "I am glad to say 65 startups from India, under NITI Aayog they all came, showing that technology to a lot of people, what India can do, how India can innovate for the world. They are vibrant because I was a startup in 1997." He further said that earlier United States was the centre of startups but for the first time Indians are getting exposure in France. DCGI nod to Bharat Biotech to conduct clinical trials of intranasal Covid-19  vaccine BBV154 "I am so happy to say the French government is very practical. They are really encouraging India and with truthfully a good heart. Again, they are really pushing how more the government can work together. How about the country's startups can work together? How government policies can create an ecosystem that is scalable, even French President Macron was talking about how to scale it up between the two partnerships, how to scale up for globe and the digitalization all that is talking about infrastructure, digitalization all that they are talking and that is a good sign between the two countries and the first time French is coming closer to India," Dr Ella said. Also Read | PM Modi condemns ‘barbaric attack’ on Kabul gurdwara -PTC News


Top News view more...

Latest News view more...

PTC NETWORK